EJ Palmer Consulting
Displaying Clients by Service Provided: Investor Relations
Investor Relations is the communication of information and insight between a company and the investment community. This process enables a full appreciation of the company’s business activities, strategy and prospects and allows the market to make an informed judgement about the fair value and appropriate ownership of a company.
Clear and consistent communication with those that own shares in your company and those that may do so in the future is a prerequisite for driving shareholder value, reducing share price volatility and keeping your investors on-side.
Good understanding of your strategy, key messages and equity story will enable your company manage its way successfully through times of both prosperity and challenge. IR is an important tool which a company can use in the execution of its strategy, for example in fund raisings and expansion of the shareholder base.
EJ Palmer Consulting’s IR services include:
- Business plan optimisation
- Analysis of your company’s equity story and investment messages
- Corporate Governance and IR regulation advisory
- Interaction with buy- and sell-side analysts
- Development of roadshow presentations
- Managing the financial calendar
- Annual reports
- Web site development
EJPC is working with Carritech under a Department of Business, Innovation and Skills life sciences mentoring scheme led by Stevenage Bioscience Catalyst.
EJPC worked with new and existing pharma and biotech clients on financial communications and investor relations.
Revision and update of the company's business plan.
Provision of an investment analysis of an unlisted UK biotech company.
Advising on a communications and investor relations strategy following the company's recent Series A fundraising.
Inivata is a global clinical cancer genomics company employing the precision of circulating tumor DNA (ctDNA) analysis to improve personalized healthcare in oncology.
In this project EJPC investigated the perceptions held by a certain type of investor and provided recommendations on further engagement.
As a healthcare portfolio consultant, EJPC advised on and monitored investments. Board observer role at Sirigen Group Ltd, sold to Becton Dickinson in 2012 with a return of 2.5-4x.
EJPC produced an updated analyst presentation for this AIM company.
2011 Annual Report text.